MarketBeat on MSN
Castle Biosciences Q2 Earnings Call Highlights
Castle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, ...
Most people think that acid reflux always causes heartburn. But according to Dr Saurabh Sethi, that is not always true. Dr ...
Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsCamilla Zuckero - Vice President of Investor ...
Hosted on MSN
Lucid says $44.8M pro forma cash extends runway well into 2027 as it awaits Medicare LCD
"We performed 3,177 EsoGuard tests in the first quarter of this year and this generated revenue of $1.3 million." (Chairman & CEO Lishan Aklog) "We also importantly strengthened our balance sheet with ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended June 30, 2026.
A pointed exchange between Justice Amy Coney Barrett and Solicitor General D. John Sauer stood out during Wednesday’s Supreme Court hearing on President Donald Trump’s use of emergency powers to ...
Delivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025Raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results